CA1003402A - Process for the separation of steroisomeric mixtures into their components and components obtained hereby - Google Patents

Process for the separation of steroisomeric mixtures into their components and components obtained hereby

Info

Publication number
CA1003402A
CA1003402A CA171,781A CA171781A CA1003402A CA 1003402 A CA1003402 A CA 1003402A CA 171781 A CA171781 A CA 171781A CA 1003402 A CA1003402 A CA 1003402A
Authority
CA
Canada
Prior art keywords
components
separation
obtained hereby
steroisomeric
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA171,781A
Other languages
English (en)
Other versions
CA171781S (en
Inventor
Karl G. Claeson
Ralph L. Brattsand
Bror A. Thalen
Bo T. Af Ekenstam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saab Bofors AB
Original Assignee
Bofors AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors AB filed Critical Bofors AB
Application granted granted Critical
Publication of CA1003402A publication Critical patent/CA1003402A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA171,781A 1972-05-19 1973-05-18 Process for the separation of steroisomeric mixtures into their components and components obtained hereby Expired CA1003402A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (fi) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
CA1003402A true CA1003402A (en) 1977-01-11

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA171,781A Expired CA1003402A (en) 1972-05-19 1973-05-18 Process for the separation of steroisomeric mixtures into their components and components obtained hereby

Country Status (17)

Country Link
US (1) US3928326A (fi)
JP (1) JPS547794B2 (fi)
BE (1) BE799728A (fi)
CA (1) CA1003402A (fi)
CY (1) CY1012A (fi)
DE (1) DE2323216C3 (fi)
DK (1) DK133249C (fi)
FI (1) FI50711C (fi)
FR (1) FR2185406B1 (fi)
GB (1) GB1428416A (fi)
HK (1) HK49079A (fi)
IL (1) IL42154A (fi)
KE (1) KE2969A (fi)
NL (1) NL175917C (fi)
SE (1) SE378110B (fi)
SU (1) SU468408A3 (fi)
ZA (1) ZA732956B (fi)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
ATE183192T1 (de) * 1993-01-08 1999-08-15 Astra Ab Neue colon-oder ilean-spezifische steroid derivate
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Iv型ホスホジエステラーゼの阻害剤
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
JP2007532551A (ja) 2004-04-09 2007-11-15 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP2010514777A (ja) 2006-12-26 2010-05-06 ファーマサイクリックス,インク. 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
NZ579645A (en) * 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
ME01331B (me) * 2009-09-11 2013-12-20 Chiesi Farm Spa Derivati izoksazolidina
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
ES2691643T3 (es) 2012-08-24 2018-11-28 Board Of Regents, The University Of Texas System Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
EP3624894A1 (en) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
SG11202004151YA (en) 2017-11-07 2020-06-29 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
CN112004557B (zh) 2018-01-08 2024-07-30 里珍纳龙药品有限公司 类固醇类化合物及其抗体偶联物
AU2019265703A1 (en) 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN115087638B (zh) 2019-12-17 2023-11-24 默沙东公司 Prmt5抑制剂
TW202423928A (zh) 2022-09-02 2024-06-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之拓樸異構酶-1抑制劑醫藥組合物及其用途
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
TW202430140A (zh) 2022-12-14 2024-08-01 美商默沙東有限責任公司 奧里斯他汀(auristatin)連接子藥物(payload)、醫藥組合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
DE2323216A1 (de) 1973-11-29
SU468408A3 (ru) 1975-04-25
DE2323216C3 (de) 1978-06-22
AU5525273A (en) 1974-11-07
KE2969A (en) 1979-07-20
FR2185406A1 (fi) 1974-01-04
FR2185406B1 (fi) 1976-12-31
NL175917C (nl) 1985-01-16
NL7306979A (fi) 1973-11-21
NL175917B (nl) 1984-08-16
GB1428416A (en) 1976-03-17
CY1012A (en) 1979-11-23
HK49079A (en) 1979-07-27
FI50711C (fi) 1976-06-10
ZA732956B (en) 1974-04-24
DE2323216B2 (de) 1977-11-03
FI50711B (fi) 1976-03-01
DK133249B (da) 1976-04-12
DK133249C (da) 1976-09-13
US3928326A (en) 1975-12-23
JPS4941379A (fi) 1974-04-18
BE799728A (fr) 1973-09-17
IL42154A (en) 1976-12-31
JPS547794B2 (fi) 1979-04-10
SE378110B (fi) 1975-08-18
IL42154A0 (en) 1973-07-30

Similar Documents

Publication Publication Date Title
CA1003402A (en) Process for the separation of steroisomeric mixtures into their components and components obtained hereby
PH11742A (en) Process for the separation of isoprene
CA998695A (en) Process for the separation of dihydroperoxides
AU468562B2 (en) Process for separation of wholewheat kernel components
CA977203A (en) Process for the manufacture of protein-containing substances
CA969483A (en) Process for the chromatographic separation of mixtures
HU172623B (hu) Sposob kondensacii vozdukha i ego komponentov
AU472802B2 (en) Process for the preparation of 3-nitro-4-amino-toluene
AU477038B2 (en) Process for the preparation of alpha-6-deoxytetracyclines
AU471441B2 (en) Process for the preparation of 2-hydrazino-benzothiazoles
AU474746B2 (en) Process for the preparation of thiazole-sulphenamides
CA1018182A (en) Process for the preparation of alkylene-bis-amides
CA1005058A (en) Process for the preparation of unsymmetrically-substituted alkanolamino-s-triazines
AU478324B2 (en) A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
CA893621A (en) Process for the separation of al and si
CA1011263A (en) Process for the separation of hydrocarbon mixtures
CA1001661A (en) Process for the separation of phenols
CA905089A (en) Structural units and method of forming the same
CA1006114A (en) Process for the preparation of chloroiminophosgene
CA895492A (en) Process and device for the separation of molecules of different masses
CA908181A (en) Process for the separation of binary mixtures
CA891030A (en) Process and apparatus for the separation of oil from an oil-water-mixture
CA915379A (en) Method for the production of rapidly removable separating walls and structure comprising such walls and components for performing the method
CA899249A (en) Process and apparatus for the separation of two immiscible liquids
CA833497A (en) Process for the separation of sugar mixtures